Radha K Dhiman1,2,3,4, Gagandeep S Grover5, Madhumita Premkumar6. 1. Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. rkpsdhiman@hotmail.com. 2. Technical Resource Group - National Viral Hepatitis Control Program (NVHCP), Government of India, New Delhi, India. rkpsdhiman@hotmail.com. 3. Punjab Government, Punjab, India. rkpsdhiman@hotmail.com. 4. Injection Safety Project, Punjab Government, Punjab, India. rkpsdhiman@hotmail.com. 5. Hepatitis C Virus Infection, Directorate of Health and Family Welfare, Punjab, India. 6. Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Abstract
PURPOSE OF REVIEW: Hepatitis C virus (HCV) infection is a principal cause of morbidity, mortality, and economic burden, and the global elimination of HCV is now considered a public health objective. Globally, an estimated 71 million have chronic HCV infection with an estimated annual mortality of 3,99,000. RECENT FINDINGS: The 69th World health Assembly has endorsed the global HCV elimination strategy by 2030, which is made possible because of all oral, cost-effective, efficacious, generic direct-acting antivirals. The public health strategy targets not only diagnosed chronic hepatitis C patients but also asymptomatic undiagnosed HCV-infected individuals, persons living with human immunodeficiency virus (HIV), post-transplant, thallasemia, persons who inject drugs, and the pediatric population. Mobilization of state-sponsored HCV elimination programs in a global coalition against HCV has taken root in Egypt, India, Georgia, Mongolia, China, Australia, and Brazil. This review summarizes current HCV elimination initiatives in terms of medical progress, barriers to HCV elimination, and current gaps in knowledge and social outreach from the public health perspective.
PURPOSE OF REVIEW: Hepatitis C virus (HCV) infection is a principal cause of morbidity, mortality, and economic burden, and the global elimination of HCV is now considered a public health objective. Globally, an estimated 71 million have chronic HCV infection with an estimated annual mortality of 3,99,000. RECENT FINDINGS: The 69th World health Assembly has endorsed the global HCV elimination strategy by 2030, which is made possible because of all oral, cost-effective, efficacious, generic direct-acting antivirals. The public health strategy targets not only diagnosed chronic hepatitis C patients but also asymptomatic undiagnosed HCV-infected individuals, persons living with human immunodeficiency virus (HIV), post-transplant, thallasemia, persons who inject drugs, and the pediatric population. Mobilization of state-sponsored HCV elimination programs in a global coalition against HCV has taken root in Egypt, India, Georgia, Mongolia, China, Australia, and Brazil. This review summarizes current HCV elimination initiatives in terms of medical progress, barriers to HCV elimination, and current gaps in knowledge and social outreach from the public health perspective.
Entities:
Keywords:
Global Strategy Against Viral Hepatitis; HCV Elimination; Hepatitis C Virus; public health
Authors: Jason Grebely; Olav Dalgard; Brian Conway; Evan B Cunningham; Philip Bruggmann; Behzad Hajarizadeh; Janaki Amin; Julie Bruneau; Margaret Hellard; Alain H Litwin; Philippa Marks; Sophie Quiene; Sharmila Siriragavan; Tanya L Applegate; Tracy Swan; Jude Byrne; Melanie Lacalamita; Adrian Dunlop; Gail V Matthews; Jeff Powis; David Shaw; Maria Christine Thurnheer; Martin Weltman; Ian Kronborg; Curtis Cooper; Jordan J Feld; Chris Fraser; John F Dillon; Phillip Read; Ed Gane; Gregory J Dore Journal: Lancet Gastroenterol Hepatol Date: 2018-01-06
Authors: Marjolein van Tilborg; Saeed H Al Marzooqi; William W L Wong; Raoel Maan; Johannes Vermehren; Benjamin Maasoumy; Tony Mazzulli; Shelly Bolotin; Gary Garber; Fiona Guerra; Christopher R Flud; Matthew Kowgier; Harry L Janssen; Robert J de Knegt; Jean-Michel Pawlotsky; Gavin A Cloherty; Andres Duarte-Rojo; Christoph Sarrazin; Heiner Wedemeyer; Jordan J Feld Journal: Lancet Gastroenterol Hepatol Date: 2018-09-28
Authors: Meghan D Morris; Stephen Shiboski; Julie Bruneau; Judith A Hahn; Margaret Hellard; Maria Prins; Andrea L Cox; Gregory Dore; Jason Grebely; Arthur Y Kim; Georg M Lauer; Andrew Lloyd; Thomas Rice; Naglaa Shoukry; Lisa Maher; Kimberly Page Journal: Clin Infect Dis Date: 2017-04-01 Impact factor: 9.079